Warfarin Sensitivity Genotyping
Genotype-guided Dosing
August 2008
When using genotype guided dosing, you can explain all but about 32% of dosing variability if you consider co-medications, non-genetic factors such as age, weight and also the genotypes for the CYP2C9 and the VKORC1 alleles. This is in contrast to how we currently do this where we look at weight, age and co-medications where roughly 70% of dosing variability has to be dealt with empirically.
Genotype-guided Dosing |
Jump to section:
- Introduction
- Warfarin
- Warfarin Anticoagulation
- Warfarin
- Warfarin Monitoring
- Therapeutic Graph
- INR Variability in a 74 Year-old Male
- Warfarin and Bleeding Events
- Warfarin Metabolism
- Polymorphisms and Warfarin Sensitivity
- Polymorphisms and Warfarin Sensitivity
- Summary of Polymorphisms and Warfarin Pharmacokinetics5
- CYP2C9 Association Study
- PGx-Guided Warfarin Dosing7
- Warfarin Pharmacodynamics
- Polymorphisms and Warfarin Sensitivity
- VKORC1 Promoter Polymorphism6
- CYP2C9 and VKORC1 Interaction8
- Genotype-guided Warfarin Dosing9
- Genotype-guided Dosing
- Summary
- Orthopedic Algorithm10
- Significant Warfarin Drug Interactions
- Differential Effect of Drugs
- Patient Case: Rapidly Increasing INR
- References
- Questions?
External
link
PDF
document
Excel
document
Word
document